Welcome to our dedicated page for Doximity news (Ticker: DOCS), a resource for investors and traders seeking the latest updates and insights on Doximity stock.
Doximity reports news about its digital platform for U.S. medical professionals, including tools for clinical collaboration, medical news and research, career and on-call management, documentation workflows, and virtual patient visits. Company updates commonly cover quarterly financial results, platform engagement, workflow products, and AI-powered clinical reference and search capabilities.
Recurring developments also include Doximity Dialer telehealth recognition, physician research on AI adoption, and the integration of Pathway Medical into Doximity's clinical reference offerings. The company's news flow links product expansion with its verified medical-professional network and its role in digital workflow tools built for physicians.
Doximity (NYSE: DOCS) reported fiscal 2027 Q1 revenue of $156.6 million, up 7% year-over-year, for the quarter ended June 30, 2026. Net income was $24.3 million with a 15.5% margin, while non-GAAP net income reached $55.0 million, a 35.1% margin. Adjusted EBITDA was $74.8 million, down 6% year-over-year, with a 47.7% margin.
Operating cash flow was $42.0 million and free cash flow $39.6 million, both declining over 30% year-over-year. Doximity ended the quarter with $273.6 million in cash and equivalents and $414.2 million in marketable securities. The company guided Q2 revenue to $170–171 million and full-year fiscal 2027 revenue to $671–681 million, with adjusted EBITDA guidance of $80.5–81.5 million for Q2 and $309–329 million for the year.
Doximity (NYSE:DOCS) announced it will release financial results for its fiscal first quarter ended June 30, 2026, after market close on August 6, 2026. The company will host a conference call and live webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the results, with access and replay available via its Investor Relations website.
Doximity (NYSE: DOCS) reported that its HIPAA-compliant clinical AI platform, Doximity Ask, ranked first on the real-world clinical sample of the independent NOHARM safety benchmark, outperforming OpenEvidence, GPT-5.6 Sol, Claude Fable 5 and other frontier models.
The NOHARM study was conducted by ARISE, a clinical AI research team led by physicians from Stanford and Harvard medical schools, using simulated patient cases. According to Doximity, Ask’s performance is linked to extensive physician authorship via its PeerCheck program, where more than 11,000 cited physician experts have reviewed and refined outputs. Doximity’s Clinical AI Suite has been reviewed, approved and deployed across over 150 health systems, including 8 of the top 20 U.S. hospitals, and incorporates end-to-end encryption, role-based access controls, audit logging and session isolation.
Doximity (NYSE:DOCS) announced that co-founder and CEO Jeff Tangney will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026, at 4:40 p.m. Central Time.
The event targets growth-focused investors and analysts.
Doximity (NYSE:DOCS) announced a partnership with Aledade to integrate Doximity’s HIPAA-compliant Clinical AI Suite into Aledade Assist, a value-based care EHR overlay.
The integration brings Scribe ambient notetaking and Ask clinical AI assistant, including PeerCheck™ validation by 10,000+ physician authors, to independent primary care practices.
Doximity (NYSE:DOCS) reported fiscal Q4 2026 revenue of $145.4 million, up 5% year-over-year, and fiscal 2026 revenue of $644.9 million, up 13%. Net income was $196.1 million with a 30.4% margin, and free cash flow reached $317.5 million, both up 19%.
The company highlighted record engagement from over 800,000 active prescribers using its workflow tools, growing use of its clinical AI, new partnerships with Aledade and Photon, leadership appointments of a new CFO and President, and issued fiscal 2027 revenue and adjusted EBITDA guidance.
Doximity (NYSE:DOCS) will report fiscal fourth quarter and full year results for the period ended March 31, 2026 on May 13, 2026 after market close. A conference call and webcast is scheduled for 2:00 p.m. PT / 5:00 p.m. ET. A replay will be posted on the investor relations website.
Doximity (NYSE: DOCS) released a national physician survey showing broad AI interest but notable accuracy concerns. 94% of physicians are using or interested in AI; 54% currently use it and 37% use it at least daily. Adoption rose from 47% (Apr 2025) to 63% (Jan 2026).
Physicians reported use for literature search and voice-based documentation; 71% cited accuracy and reliability as their top concern. The survey covers 3,151 U.S. physicians across 15 specialties.
Doximity (NYSE: DOCS) announced that Doximity Dialer was named the #1 Telehealth Video Conferencing Platform in the 2026 Best in KLAS Report for the fifth consecutive year, earning A-level ratings across categories and A+ for culture, loyalty, and value.
Engagement metrics show clinicians completed more than 300,000 Dialer calls each workday last quarter and a single-day record of 720,000 HIPAA-compliant calls and texts.
Doximity (NYSE: DOCS) reported fiscal 2026 third quarter results for the period ended December 31, 2025, with revenue of $185.1 million (up 10% YoY) and net income of $61.6 million (33.3% margin). Adjusted EBITDA was $111.4 million (60.2% margin). Operating cash flow was $60.9 million and free cash flow was $58.5 million. The company provided Q4 revenue guidance of $143–144 million and full-year revenue guidance of $642.5–643.5 million. The board authorized a $500 million share repurchase program.